Patents by Inventor Lawrence S. Melvin, Jr.

Lawrence S. Melvin, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZOTHIAZOLE AND QUINOLINE DERIVATIVES AND THEIR USE
    Publication number: 20240116885
    Abstract: Provided are compounds of Formula (I) or (II) and related compositions and methods for their use as inhibitors of alpha-kinase 1 (ALPK1).
    Type: Application
    Filed: September 23, 2021
    Publication date: April 11, 2024
    Inventors: Danyang Liu, Cong Xu, Lawrence S. Melvin, Jr., Xiong Wei, Tongruei Raymond Li, Jieqing Fan, Yanfang Pan, Huaixin Dang, Henri Lichenstein, Tian Xu
  • ALPHA PROTEIN KINASE 1 INHIBITORS AND METHODS OF USE
    Publication number: 20240109853
    Abstract: Provided are compounds of Formula I, compositions and methods for their use as inhibitors of alpha-kinase 1 (ALPK1).
    Type: Application
    Filed: September 23, 2021
    Publication date: April 4, 2024
    Inventors: Danyang Liu, Cong Xu, Lawrence S. Melvin, Jr., Xiong Wei, Tongruei Raymond Li, Jieqing Fan, Yanfang Pan, Huaixin Dang, Henri Lichenstein, Tian Xu
  • RAPAMYCIN FOR THE TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS
    Publication number: 20230355516
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Application
    Filed: July 20, 2023
    Publication date: November 9, 2023
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Thomas Armer, Lawrence S. Melvin, JR.
  • Rapamycin for the treatment of lymphangioleiomyomatosis
    Patent number: 11744797
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: September 5, 2023
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Thomas Armer, Lawrence S. Melvin, Jr.
  • INHALABLE RAPAMYCIN FORMULATION FOR THE TREATMENT OF PULMONARY HYPERTENSION
    Publication number: 20230255944
    Abstract: The present invention relates to methods and compositions for the treatment and prophylaxis of pulmonary arterial hypertension (PAH) in a human subject in need of such treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation of a composition comprising rapamycin or a prodrug or derivative thereof.
    Type: Application
    Filed: October 14, 2022
    Publication date: August 17, 2023
    Applicant: AI Therapeutics, Inc.
    Inventors: Thomas Armer, Lawrence S. Melvin, JR., Jonathan M. Rothberg, Henri Lichenstein
  • INHALABLE RAPAMYCIN FORMULATION FOR TREATING AGE-RELATED CONDITIONS
    Publication number: 20230240986
    Abstract: The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.
    Type: Application
    Filed: April 10, 2023
    Publication date: August 3, 2023
    Inventors: Thomas Armer, Lawrence S. Melvin, JR., Jonathan M. Rothberg, Henri Lichenstein
  • Inhalable rapamycin formulation for treating age-related conditions
    Patent number: 11648199
    Abstract: The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: May 16, 2023
    Assignee: Al Therapeutics, Inc.
    Inventors: Thomas Armer, Lawrence S. Melvin, Jr., Jonathan M. Rothberg, Henri Lichenstein
  • Inhalable rapamycin formulation for the treatment of pulmonary hypertension
    Patent number: 11491143
    Abstract: The present invention relates to methods and compositions for the treatment and prophylaxis of pulmonary arterial hypertension (PAH) in a human subject in need of such treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation of a composition comprising rapamycin or a prodrug or derivative thereof.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: November 8, 2022
    Assignee: AI Therapeutics, Inc.
    Inventors: Thomas Armer, Lawrence S. Melvin, Jr., Jonathan M. Rothberg, Henri Lichenstein
  • RAPAMYCIN FOR THE TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS
    Publication number: 20220054410
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Application
    Filed: August 27, 2021
    Publication date: February 24, 2022
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Thomas Armer, Lawrence S. Melvin, JR.
  • Rapamycin for the treatment of lymphangioleiomyomatosis
    Patent number: 11123289
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: September 21, 2021
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Thomas Armer, Lawrence S. Melvin, Jr.
  • Inhalable rapamycin formulation for treating age-related conditions
    Patent number: 11103449
    Abstract: The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: August 31, 2021
    Assignee: AI Therapeutics, Inc.
    Inventors: Thomas Armer, Lawrence S. Melvin, Jr., Jonathan M. Rothberg, Henri Lichenstein
  • INHALABLE RAPAMYCIN FORMULATION FOR TREATING AGE-RELATED CONDITIONS
    Publication number: 20210212942
    Abstract: The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.
    Type: Application
    Filed: March 31, 2021
    Publication date: July 15, 2021
    Inventors: Thomas Armer, Lawrence S. Melvin, JR., Jonathan M. Rothberg, Henri Lichenstein
  • INHALABLE RAPAMYCIN FORMULATION FOR THE TREATMENT OF PULMONARY HYPERTENSION
    Publication number: 20200306230
    Abstract: The present invention relates to methods and compositions for the treatment and prophylaxis of pulmonary arterial hypertension (PAH) in a human subject in need of such treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation of a composition comprising rapamycin or a prodrug or derivative thereof.
    Type: Application
    Filed: December 27, 2019
    Publication date: October 1, 2020
    Inventors: Thomas Armer, Lawrence S. Melvin, JR., Jonathan M. Rothberg, Henri Lichenstein
  • RAPAMYCIN FOR THE TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS
    Publication number: 20200276120
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Application
    Filed: November 26, 2019
    Publication date: September 3, 2020
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Thomas Armer, Lawrence S. Melvin, JR.
  • Rapamycin for the treatment of lymphangioleiomyomatosis
    Patent number: 10307371
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 4, 2019
    Assignee: AI Therapeutics, Inc.
    Inventors: Thomas Armer, Lawrence S. Melvin, Jr., Jonathan M. Rothberg, Henri Lichenstein
  • Rapamycin for the treatment of lymphangioleiomyomatosis
    Patent number: 10307370
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: June 4, 2019
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Thomas Armer, Lawrence S. Melvin, Jr.
  • INHALABLE RAPAMYCIN FORMULATION FOR TREATING AGE-RELATED CONDITIONS
    Publication number: 20190133938
    Abstract: The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.
    Type: Application
    Filed: July 23, 2018
    Publication date: May 9, 2019
    Inventors: Thomas Armer, Lawrence S. Melvin, JR., Jonathan M. Rothberg, Henri Lichenstein
  • RAPAMYCIN FOR THE TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS
    Publication number: 20180200184
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Application
    Filed: November 3, 2017
    Publication date: July 19, 2018
    Inventors: Thomas Armer, Lawrence S. Melvin, JR., Jonathan M. Rothberg, Henri Lichenstein
  • AN INHALABLE RAPAMYCIN FORMULATION FOR THE TREATMENT OF PULMONARY HYPERTENSION
    Publication number: 20170304276
    Abstract: The present invention relates to methods and compositions for the treatment and prophylaxis of pulmonary arterial hypertension (PAH) in a human subject in need of such treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation of a composition comprising rapamycin or a prodrug or derivative thereof.
    Type: Application
    Filed: October 7, 2015
    Publication date: October 26, 2017
    Inventors: Thomas Armer, Lawrence S. Melvin, Jr., Jonathan M. Rothberg, Henri Lichenstein
  • Apoptosis signal-regulating kinase inhibitors
    Patent number: RE48711
    Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: August 31, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Britton Corkey, Michael Graupe, Keith Koch, Lawrence S. Melvin, Jr., Gregory Notte